2014
DOI: 10.1161/hypertensionaha.114.03477
|View full text |Cite
|
Sign up to set email alerts
|

Down But Not Out

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
3
0

Year Published

2016
2016
2020
2020

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(3 citation statements)
references
References 12 publications
0
3
0
Order By: Relevance
“…Plasma ET-1concentrations during preeclampsia was approximately two- to three-times higher than normal levels, and ET-1 has significant long-term effects on arterial pressure regulation [8-10]. However, some studies have reported that there was no elevation in plasma endothelin in preeclampsia patients [11]. In addition, ET-1 is considered to be involved in the progression of preeclampsia rather than the initiation of the disease; thus, the exact role of endothelin is unknown [7].…”
Section: Introductionmentioning
confidence: 99%
“…Plasma ET-1concentrations during preeclampsia was approximately two- to three-times higher than normal levels, and ET-1 has significant long-term effects on arterial pressure regulation [8-10]. However, some studies have reported that there was no elevation in plasma endothelin in preeclampsia patients [11]. In addition, ET-1 is considered to be involved in the progression of preeclampsia rather than the initiation of the disease; thus, the exact role of endothelin is unknown [7].…”
Section: Introductionmentioning
confidence: 99%
“…The biological effects of ET-1 are mediated by two G protein-coupled receptors, ETA receptor (ETAR) and ETB receptor (ETBR) [ 8 , 9 ]. ETAR promotes vasoconstriction, cell growth, adhesion and thrombosis, while ETBR promotes vasodilation [ 10 , 11 , 12 ]. Endothelin receptor antagonists have been developed for the treatment of multiple cardiovascular diseases, such as hypertension and systemic sclerosis [ 10 , 13 , 14 , 15 ].…”
Section: Introductionmentioning
confidence: 99%
“…ETAR promotes vasoconstriction, cell growth, adhesion and thrombosis, while ETBR promotes vasodilation [ 10 , 11 , 12 ]. Endothelin receptor antagonists have been developed for the treatment of multiple cardiovascular diseases, such as hypertension and systemic sclerosis [ 10 , 13 , 14 , 15 ]. Moreover, they also show therapeutic action for glaucoma [ 16 ], preeclampsia [ 17 ], diabetic kidney disease [ 18 ] and ovarian tumors [ 19 ].…”
Section: Introductionmentioning
confidence: 99%